Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver

The aim of this study was to evaluate safety and survival following hepatic artery embolization (HAE) for metastatic solitary fibrous tumor (SFT) in the liver. All patients with SFT metastatic to liver treated with HAE were retrospectively analyzed. Tumor response was evaluated using mRECIST. Object...

Full description

Saved in:
Bibliographic Details
Published in:Complexity (New York, N.Y.) N.Y.), 2019, Vol.2019 (2019), p.1-6
Main Authors: Kingham, Peter T., Tap, William D., Jarnagin, William, Yarmohammadi, Hooman, Getrajdman, George I., Covey, Anne M., Brown, Karen T., Boas, Franz E., Ziv, Etay, Brody, Lynn A., Erinjeri, Joseph P., Velayati, Sara, Solomon, Stephen B.
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Cancer therapies
Care and treatment
Chemotherapy
Complications and side effects
Demographics
Development and progression
Embolization
Head and neck
Hepatic artery
Laboratories
Liver
Liver cancer
Medical prognosis
Medical records
Metastases
Metastasis
NMR
Nuclear magnetic resonance
Oncology
Patients
Pelvis
Pleura
Radiation therapy
Sepsis
Surgery
Survival
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate safety and survival following hepatic artery embolization (HAE) for metastatic solitary fibrous tumor (SFT) in the liver. All patients with SFT metastatic to liver treated with HAE were retrospectively analyzed. Tumor response was evaluated using mRECIST. Objective response, overall survival (OS), and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariate Cox proportional hazard ratio. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Twelve patients (6 males and 6 females, mean age: 42.5 ± 13 years; 24–65) were treated with 33 embolizations. Anatomical sites of origin for SFT were the head and neck (n = 6; 50%), pelvis (n = 2), pleura (n = 2), retroperitoneal (n = 1), and thigh (n = 1). The median follow-up from first HAE was 4.5 years (3–7.9). 84% of the patients showed objective response [42% complete response (CR) plus 42% partial response (PR)] to HAE by mRECIST (95% CI, 60–99%). Patients with CR to HAE had significantly higher OS compared to others (p
ISSN:1076-2787
1357-714X
1099-0526
1369-1643
DOI:10.1155/2019/3060658